Premium
PARTIAL AGONIST BEHAVIOUR OF ADENOSINE 5′O‐(2‐THIODIPHOSPHATE) ON HUMAN PLATELETS
Author(s) -
CUSACK N.J.,
HOURANI S.M.O.
Publication year - 1981
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/j.1476-5381.1981.tb10436.x
Subject(s) - adenosine , adenosine diphosphate , adenylate kinase , agonist , platelet , chemistry , alpha (finance) , cyclase , endocrinology , medicine , partial agonist , prostaglandin , prostaglandin h2 , beta (programming language) , platelet aggregation , biochemistry , receptor , biology , thromboxane a2 , construct validity , nursing , computer science , patient satisfaction , programming language
1 The effects of an adenosine diphosphate (ADP) analogue, adenosine 5′‐O‐(2‐thiodiphosphate) (ADP‐β‐S), in which a terminal phosphate oxygen has been replaced by sulphur, were studied on human platelets. 2 ADP‐/3‐S induced platelet aggregation and inhibited prostaglandin E 1 (PGE 1)‐stimulated adenylate cyclase but in both cases was less potent than ADP and did not achieve the same maximal effects. 3 Both actions of ADP could be inhibited by the simultaneous addition of ADP‐β‐S (50 μm). 4 Aggregation induced by 11α, 9α‐epoxymethano prostaglandin H 2 (a stable endoperoxide analogue) was not inhibited by simultaneous addition of ADP‐β‐S (50 μm). 5 The behaviour of ADP‐β‐S towards human platelets was consistent with it being a partial agonist.